Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.

British journal of cancer - 1 Nov 2023

Shen Michelle, Liu Shiqin, Toland Angus, Hsu En-Chi, Hartono Alifiani B, Alabi Busola R, Aslan Merve, Nguyen Holly M, Sessions Conner J, Nolley Rosalie, Shi Chanjuan, Huang Jiaoti, Brooks James D, Corey Eva, Stoyanova Tanya

Abstract excerpt

BACKGROUND: Neuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as neuroendocrine prostate cancer (NEPC) and small-cell lung cancer (SCLC). Expression levels of current neuroendocrine markers exhibit high case-by-case variability, so multiple markers are used in combination to identify SCNCs. Here, we report that ACAA2 is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Carcinoma, Small Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Lung Neoplasms

Share to Phenotype

Share to Prostatic Neoplasms

Share to RNA, Messenger

Share to Small Cell Lung Carcinoma

Source

Open in PubMed Open full text

Identifiers

PMID: 37798372
DOI: 10.1038/s41416-023-02448-y
PMCID: PMC10667239

Genes

ACAA2
PC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.PMID 37798372Read ↗

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinomaSemantic proximity Read ↗

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate AdenocarcinomaSemantic proximity Read ↗

The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanismsSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic AlterationsSemantic proximity Read ↗

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read ↗

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Semantic proximity Read ↗

Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptorsSemantic proximity Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease statusSemantic proximity Read ↗

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancerSemantic proximity Read ↗

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.